This record was last updated March 30, 2025 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
Evaluate the efficacy and safety of immune checkpoint inhibitors combined with chidamide as an "activate and kill" strategy to extend viral rebound time, reduce the HIV reservoir, and achieve functional cure.